FDA panel backs Janssen's fast-acting depression treatment

A lack of available treatment options swayed a 14-2 panel vote in favor of recommending approval of intranasal Spravato esketamine (formerly JNJ-54135419) from Janssen Pharmaceuticals Inc. to treat patients with treatment-resistant depression. If approved, Spravato would provide patients that have

Read the full 401 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE